A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Latest Information Update: 18 Jul 2022
At a glance
- Drugs Daratumumab (Primary) ; Talacotuzumab (Primary)
- Indications Myelodysplastic syndromes
- Focus Proof of concept; Therapeutic Use
- Sponsors Janssen Research & Development
- 27 Jan 2022 Status changed from active, no longer recruiting to completed.
- 26 Nov 2021 This trial has been completed in Italy, according to European Clinical Trials Database record.
- 19 Nov 2021 This trial has been completed in Belgium as per European Clinical Trials Database.